Author + information
- Ana Marcano,
- David Vivas,
- Juan Carlos Gomez-Polo,
- Antonio Tello,
- Jesus De La Hera,
- Francisco Marin,
- Inmaculada Roldan and
- Jose Luis Ferreiro
Background: Women with an acute coronary syndrome (ACS) are less likely to receive recommended therapies, such as more potent antiplatelet agents. This analysis aims to evaluate the use of P2Y12 receptor antagonists according to gender.
Methods: Subanalysis of a prospective, multicenter, observational study, conducted in a Spanish population of ACS patients on dual antiplatelet therapy undergoing PCI. Responsiveness to P2Y12 antagonists was assessed the next morning after the procedure with the Verify Now P2Y12 Assay and VASP analysis, using standard cutoff points to determine high on-treatment platelet reactivity (HTPR).
Results: Among the first 394 patients included (preliminary results), female patients (n=90, 22.8%) were older (68.6 vs. 63.7 years old) and had more frequently diabetes mellitus (43.3% vs. 28.6%) and chronic kidney disease (31.5% vs. 15.0%) than male subjects (all p<0.01). Clopidogrel treatment was more frequent in women (48.9% vs. 30.3%; P=0.001), whereas ticagrelor or prasugrel were more commonly prescribed in men (Figure). No differences in HTPR rates to any antiplatelet agent were observed according to gender with any of the platelet function assays used.
Conclusions: The use of potent P2Y12 antagonists is less common in female ACS patients, despite presenting a greater burden of risk factors than men.
Poster Hall, Hall C
Saturday, March 18, 2017, 9:45 a.m.-10:30 a.m.
Session Title: Novel Developments in Acute Coronary Syndromes
Abstract Category: 15. Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology
Presentation Number: 1194-161
- 2017 American College of Cardiology Foundation